IRS1 and glioblastoma: For instance, the glioblastoma resistance to receptor tyrosine kinase (RTK) inhibitors has been found to involve both genetic and epigenetic mechanisms[47], resulting in subclones with a gain of copy number in the insulin receptor substrate-1(IRS1) and substrate-2 (IRS2) loci.